CRISPR Therapeutics AG (CRSP): The Biotech Stock with Biggest Upside Potential
We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...
Zacks.com on MSN2d
CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell?
Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...
Cathie Wood’s ARK Investment bought 133K shares of Crispr Therapeutics today
EST Cathie Wood’s ARK Investment bought 133K shares of Crispr Therapeutics (CRSP) todayStay Ahead of the Market:Discover outperforming ...
CRISPR Therapeutics' SWOT analysis: gene editing pioneer's stock faces pivotal year
CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...
Le Lézard6d
Synthego Signs Strategic Agreement with AstraZeneca to License CRISPR Gene Editing Enzyme
Synthego, a leading supplier of CRISPR solutions, has entered a strategic licensing agreement with global biopharmaceutical company AstraZeneca. This agreement grants Synthego a global license to ...